Fate Therapeutics (FATE) Misses Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. FND
9. DASH
10. GILD

Go back to Fate Therapeutics (FATE) Misses Q2 EPS by 8c

Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress

August 5, 2020 4:02 PM EDT

Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient

Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma

 IND Cleared for FT538, the First CRISPR-edited, iPSC-derived Cell Therapy, for AML and Multiple Myeloma

IND Cleared for FT819, the First iPSC-derived CAR T-cell Therapy, for Advanced B-cell Leukemias and Lymphomas

Worldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates Targeting up to Four Tumor-associated Antigens

... More